Sodium chloride (placebo)

DRUG6 trials

Sponsors

Bispebjerg Hospital, University of Oxford, Attgeno AB, Rigshospitalet, Denmark

Conditions

COVID-19Glucose MetabolismIron DeficiencyNAFLD (Nonalcoholic Fatty Liver Disease)Polymyalgia RheumaticaPulmonary Hypertension

Phase 1

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension

WithdrawnNCT04885491

Attgeno ABCOVID-19, Pulmonary Hypertension

Start: 2021-05-07End: 2023-04-30Updated: 2023-08-01

A First-in-Human Study to Assess the Safety and Tolerability of PDNO

CompletedNCT04891354

Attgeno ABPulmonary Hypertension

Start: 2021-02-02End: 2022-05-25Updated: 2023-01-19

Phase 2

A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in Patients With Pulmonary Hypertension After Cardiopulmonary Bypass Surgery

Attgeno ABPulmonary Hypertension

Start: 2022-10-23End: 2023-12-31Target: 12Updated: 2023-08-01

Phase 3

Etanercept Treatment in the Early Course of Polymyalgia Rheumatica

CompletedNCT00524381

Bispebjerg HospitalPolymyalgia Rheumatica

Start: 2007-08-31End: 2009-09-30Target: 40Updated: 2010-02-23

Unknown Phase

Iron Status and Human Metabolism

CompletedNCT02308449

University of OxfordIron Deficiency

Start: 2014-10-31End: 2016-01-31Updated: 2022-07-19

Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET

Active, not recruitingNCT07366710

Rigshospitalet, DenmarkGlucose Metabolism, NAFLD (Nonalcoholic Fatty Liver Disease)

Start: 2024-11-05End: 2027-10-01Target: 36Updated: 2026-02-02

Related Papers

Activity of the neuroendocrine axes in patients with polymyalgia rheumatica before and after TNF-α blocking etanercept treatment.

2012-08-159 citations

Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial.

2010-09-2061 citations